Back to Search Start Over

Evaluating immunity to <scp>SARS‐CoV</scp> ‐2 in nursing home residents using saliva <scp>IgG</scp>

Authors :
Morgan J. Katz
Christopher D. Heaney
Nora Pisanic
Leigh Smith
Benjamin F. Bigelow
Fatima Sheikh
Alec Boudreau
Kate Kruczynski
Yea‐Jen Hsu
Alejandra B. Salinas
Sara E. Cosgrove
Clare Rock
Source :
Journal of the American Geriatrics Society. 70:659-668
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

SARS-CoV-2 circulating variants coupled with waning immunity pose a significant threat to the long-term care (LTC) population. Our objective was to measure salivary IgG antibodies in residents and staff of an LTC facility to (1) evaluate IgG response in saliva post-natural infection and vaccination and (2) assess its feasibility to describe the seroprevalence over time.We performed salivary IgG sampling of all residents and staff who agreed to test in a 150-bed skilled nursing facility during three seroprevalence surveys between October 2020 and February 2021. The facility had SARS-CoV-2 outbreaks in May 2020 and November 2020, when 45 of 138 and 37 of 125 residents were infected, respectively; they offered two Federal vaccine clinics in January 2021. We evaluated quantitative IgG in saliva to the Nucleocapsid (N), Spike (S), and Receptor-binding domain (RBD) Antigens of SARS-CoV-2 over time post-infection and post-vaccination.One hundred twenty-four residents and 28 staff underwent saliva serologic testing on one or more survey visits. Over three surveys, the SARS-CoV-2 seroprevalence at the facility was 49%, 64%, and 81%, respectively. IgG to S, RBD, and N Antigens all increased post infection. Post vaccination, the infection na&#239;ve group did not have a detectable N IgG level, and N IgG levels for the previously infected did not increase post vaccination (p 0.001). Fully vaccinated subjects with prior COVID-19 infection had significantly higher RBD and S IgG responses compared with those who were infection-na&#239;ve prior to vaccination (p 0.001 for both).Positive SARS-COV-2 IgG in saliva was concordant with prior infection (Anti N, S, RBD) and vaccination (Anti S, RBD) and remained above positivity threshold for up to 9 months from infection. Salivary sampling is a non-invasive method of tracking immunity and differentiating between prior infection and vaccination to inform the need for boosters in LTC residents and staff.

Details

ISSN :
15325415 and 00028614
Volume :
70
Database :
OpenAIRE
Journal :
Journal of the American Geriatrics Society
Accession number :
edsair.doi.dedup.....7414f78be54e13181d64f1c46aa57c18
Full Text :
https://doi.org/10.1111/jgs.17660